Literature DB >> 24155380

Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain.

Dirk Eggink1, Peter H Goff, Peter Palese.   

Abstract

Influenza virus hemagglutinin consists of a highly variable and immunodominant head domain and a more conserved but immunosubdominant stalk domain. We introduced seven N-linked glycosylation sites in the hemagglutinin head domain to shield the immunodominant antigenic sites. The hyperglycosylated hemagglutinin enhanced stalk-directed seroreactivity while dampening the head response in immunized mice. Upon influenza virus challenge, mice vaccinated with the hyperglycosylated hemagglutinin were better protected against morbidity and mortality than mice receiving the wild-type hemagglutinin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24155380      PMCID: PMC3911724          DOI: 10.1128/JVI.02608-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Positive selection for gains of N-linked glycosylation sites in hemagglutinin during evolution of H3N2 human influenza A virus.

Authors:  Yoshiyuki Suzuki
Journal:  Genes Genet Syst       Date:  2011       Impact factor: 1.517

2.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

3.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

4.  Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin.

Authors:  Yuki Kobayashi; Yoshiyuki Suzuki
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

5.  Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Authors:  Rafael S Depetris; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Robert Pejchal; Umesh Katpally; Nicolette Cocco; Milind Kachare; Evan Massi; Kathryn B David; Albert Cupo; Andre J Marozsan; William C Olson; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

6.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

7.  Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.

Authors:  Robert P de Vries; Cornelis H Smit; Erwin de Bruin; Alan Rigter; Erik de Vries; Lisette A H M Cornelissen; Dirk Eggink; Nancy P Y Chung; John P Moore; Rogier W Sanders; Cornelis H Hokke; Marion Koopmans; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

8.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Authors:  Natalie Pica; Rong Hai; Florian Krammer; Taia T Wang; Jad Maamary; Dirk Eggink; Gene S Tan; Jens C Krause; Thomas Moran; Cheryl R Stein; David Banach; Jens Wrammert; Robert B Belshe; Adolfo García-Sastre; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

9.  A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Authors:  Gene S Tan; Florian Krammer; Dirk Eggink; Alita Kongchanagul; Thomas M Moran; Peter Palese
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

10.  A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

Authors:  Florian Krammer; Irina Margine; Gene S Tan; Natalie Pica; Jens C Krause; Peter Palese
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

View more
  71 in total

1.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

2.  A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors:  Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

4.  Outflanking immunodominance to target subdominant broadly neutralizing epitopes.

Authors:  Davide Angeletti; Ivan Kosik; Jefferson J S Santos; William T Yewdell; Carolyn M Boudreau; Vamsee V A Mallajosyula; Madeleine C Mankowski; Michael Chambers; Madhu Prabhakaran; Heather D Hickman; Adrian B McDermott; Galit Alter; Jayanta Chaudhuri; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

5.  Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.

Authors:  Hsin-Yu Liao; Shih-Chi Wang; Yi-An Ko; Kuo-I Lin; Che Ma; Ting-Jen Rachel Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

6.  Immunosilencing a highly immunogenic protein trimerization domain.

Authors:  Kwinten Sliepen; Thijs van Montfort; Mark Melchers; Gözde Isik; Rogier W Sanders
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

Review 7.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

8.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 9.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

10.  Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.

Authors:  Wen-Chun Liu; Jia-Tsrong Jan; Yun-Ju Huang; Ting-Hsuan Chen; Suh-Chin Wu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.